Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Expert Review of Clinical Pharmacology|February 1, 2021
Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC)Bernardo L Rapoport, Tim Cooksley, Douglas B Johnson, et al.
The Oncologist|March 22, 2015
Aprepitant and fosaprepitant: a 10-year review of efficacy and safetyMatti Aapro, Alexandra Carides, Bernardo L Rapoport, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599Corey Langer, Sigui Li, Joan Schiller, et al.
Critical Reviews in Oncology/Hematology|February 24, 2024
Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidencePere Gascón, Nadia Harbeck, Bernardo L Rapoport, et al.
Case Reports in Oncological Medicine|June 10, 2022
A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-UpAlexandra Grubnik, Yastira Ramdas, Barend Van der Bergh, et al.
Cells|July 16, 2020
High Mobility Group Box 1 in Human CancerBernardo L Rapoport, Helen C Steel, Annette J Theron, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 26, 2010
Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the artSteven M Grunberg, David Warr, Richard J Gralla, et al.
Current Issues in Molecular Biology|May 27, 2026
Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging TargetBernardo L Rapoport, Ronald Anderson, Daniel van Tonder, et al.
International Journal of Dermatology|January 20, 2011
Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsYevgeniy Balagula, Claus Garbe, Patricia L Myskowski, et al.
BMC Cancer|July 20, 2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancerThomas Kuehr, Paul Ruff, Bernardo L Rapoport, et al.
Pageof 6